

S 2828

Endocrine Disruption Prevention Act of 2009

Congress: 111 (2009–2011, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Dec 3, 2009

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Dec 3, 2009)

Official Text: <https://www.congress.gov/bill/111th-congress/senate-bill/2828>

Sponsor

Name: Sen. Kerry, John F. [D-MA]

Party: Democratic • State: MA • Chamber: Senate

Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Gillibrand, Kirsten E. [D-NY]	D · NY		Jul 28, 2010
Sen. Feinstein, Dianne [D-CA]	D · CA		Sep 22, 2010

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Dec 3, 2009

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
111 HR 4190	Identical bill	Dec 7, 2009: Referred to the Subcommittee on Health.

Endocrine Disruption Prevention Act of 2009 - Amends the Public Health Service Act to require the Director of the National Institute of Environmental Health Sciences to establish the Endocrine Disruption Prevention Program, under which the Director shall: (1) conduct and support multidisciplinary research to improve the understanding of endocrine disruption; and (2) conduct workshops and fora on health effects associated with environmental agents that may affect the endocrine system.

Requires the Director to establish an Endocrine Disruption Program Panel, which shall: (1) provide advice to the Director on the conduct and support of research; (2) evaluate existing population-level biomonitoring and biobanking surveillance and research programs and recommend changes needed to develop data on human exposures and effects to support the Program; and (3) develop a list of chemicals of concern for endocrine disruption effects and make findings with respect to such chemicals. Authorizes individuals to petition the Panel to determine whether a chemical should be listed or to revise a finding or determination based on new information.

Requires the Director, if the Panel finds that data are sufficient to determine that there is at least a minimal level of concern associated with a chemical's potential to disrupt the human endocrine system, to transmit the finding, including the routes and sources of exposure to the chemical, to each federal agency with authority to regulate the chemical. Requires each federal agency that receives such a transmission: (1) to reply to the Director describing the agency's regulatory authority, past actions in connection with the chemical, and proposed action to protect human health from the potential endocrine disruption effects of exposure to the chemical; and (2) within one year, to report on the actions taken and future actions proposed by the Agency in response to the Panel's finding.

Requires the Director to establish a program to support graduate and postdoctoral training in fields related to the prevention of endocrine disruption.

Actions Timeline

- **Dec 3, 2009:** Introduced in Senate
- **Dec 3, 2009:** Sponsor introductory remarks on measure. (CR S12324)
- **Dec 3, 2009:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.